Haisco's Class 1 Innovative Drug Ciprocopan Succinate Tablets Approved in China, Offering a New Treatment Option for Patients With PNH

Haisco’s Class 1 innovative drug ciprocopan succinate tablets (HSK39297) received NMPA marketing approval in China for complement-inhibitor–naïve adult PNH patients, adding a once-daily oral FB inhibitor to its pipeline. The article also highlights a sizable ex-China/out-license deal with Nuvectis, including $40M in upfront/near-term milestones and up to $1.421B additional milestones plus tiered double-digit royalties, supporting growth optionality for future commercialization. Reported Phase III metrics cited include 59.5% hemoglobin target attainment, +48.35 g/L hemoglobin increase, and 94.6% of patients transfusion-free, with a stated favorable safety profile.

Analysis

This is more a de-risking event for the asset class than a near-term earnings event. For Nuvectis, the important signal is that a China-origin complement program has crossed a real regulatory hurdle, which tends to improve the odds of partnerable ex-China economics even if domestic sales in China remain too small to matter.

The competitive read-through is subtle: oral, once-daily administration can pressure the convenience premium enjoyed by injectable complement franchises, but only if efficacy translates outside China and reimbursement does not force step-therapy. The bigger second-order effect is on partnering power and valuation dispersion across China biotech, where approved-in-China / licensed-out assets often get underwritten more on milestone credibility than on home-market revenue.

Tail risk is that the market over-interprets a China approval as global validation. For the next 1-3 months the stock can trade on financing and licensing headlines; over 6-18 months, the real determinant is whether ex-China development triggers are concrete and whether safety/durability data support broader adoption. If no partner update emerges or if ex-China trial requirements remain open-ended, the re-rating should fade quickly.

Key Decisions for Investors

• Small starter long NVCT on weakness, sized as event-driven optionality; hold 3-6 months for an ex-China partnering update, but cut if no concrete commercial or financing catalyst appears.
• Pair trade: long NVCT / short XBI to isolate asset-specific de-risking from the broader biotech multiple compression; target a 10-15% relative move, exit if biotech risk appetite rebounds sharply.
• No trade in ABBV on this release; the read-through to its cash flow is too indirect to matter unless a disclosed economic tie to the program surfaces.
• Set an alert for any U.S./EU development announcement or licensing expansion beyond Greater China; that is the first point where the valuation can re-rate beyond a pure sentiment pop.
• Watch for secondary risk in NVCT: if management uses the headline to raise capital without a matching partner announcement, treat that as a short-term fade signal.